The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Mycophenolate Mofetil for Ocular Inflammation
Open accessAbstract
PURPOSE To evaluate mycophenolate mofetil as a single noncorticosteroid immunosuppressive treatment for noninfectious ocular inflammatory diseases. DESIGN Retrospective cohort study. METHODS Characteristics of patients with noninfectious ocular inflammation treated with mycophenolate mofetil at 4 subspecialty clinics from 1995 to 2007 were abstracted by expert reviewers in a standardized chart review of every eye at every visit. Main outcomes measured were control of inflammation, corticosteroid-sparing effects, and discontinuation of mycophenolate mofetil (including the reasons for discontinuation). Survival analysis was used to estimate the incidence of outcomes, and to identify risk factors for each. RESULTS Among 236 patients (397 eyes) treated with mycophenolate mofetil monotherapy, 20.3%, 11.9%, and 39.8% had anterior uveitis, intermediate uveitis, and posterior uveitis or panuveitis respectively; 14% had scleritis; 7.6% had mucous membrane pemphigoid; and 6.4% had other ocular inflammatory diseases. By Kaplan-Meier estimation, complete control of inflammation--sustained over consecutive visits spanning at least 28 days--was achieved in 53% and 73% of patients within 6 months and 1 year respectively. Systemic corticosteroid dosage was reduced to 10 mg of prednisone or less, while maintaining sustained control of inflammation, in 41% and 55% of patients in 6 months and 1 year respectively. Twelve percent of patients discontinued mycophenolate mofetil within the first year because of side effects of therapy. CONCLUSIONS Given sufficient time, mycophenolate mofetil was effective in managing ocular inflammation in approximately half of the treated patients. Treatment-limiting side effects were observed in 12% of patients and typically were reversible.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
(2005) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2005.03.057 · Cited by 4,396
Goodman and Gilman's The Pharmacological Basis of Therapeutics
Fraunfelder, F. T. (1981) · American Journal of Ophthalmology · doi:10.1016/0002-9394(81)90318-4 · Cited by 1,331
Jabs, D. A., Rosenbaum, J. T., Foster, C. S., Holland, G. N., Jaffe, G. J., Louie, J. S., Nussenblatt, R. B., Stiehm, E. R., Tessler, H., Van Gelder, R. N., et al. (2000) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(00)00659-0 · Cited by 995
Self-citationThe natural history of uveitis
Nussenblatt, R. B. (1990) · International Ophthalmology · doi:10.1007/bf00163549 · Cited by 514
Self-citationMechanisms of action of mycophenolate mofetil
Allison, A. (2005) · Lupus · doi:10.1177/096120330501400102 · Cited by 480
Characterization of human type I and type II IMP dehydrogenases.
Carr, S. F., Papp, E., Wu, J. C., & Natsumeda, Y. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)74247-1 · Cited by 403
Methotrexate for Ocular Inflammatory Diseases
Gangaputra, S., Newcomb, C. W., Liesegang, T. L., Kaçmaz, R. O., Jabs, D. A., Levy-Clarke, G. A., Nussenblatt, R. B., Rosenbaum, J. T., Suhler, E. B., & Thorne, J. E. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.04.020 · Cited by 330
Self-citationAzathioprine for Ocular Inflammatory Diseases
Pasadhika, S., Kempen, J. H., Newcomb, C. W., Liesegang, T. L., Pujari, S. S., Rosenbaum, J. T., Thorne, J. E., Foster, C. S., Jabs, D. A., Levy-Clarke, G. A., et al. (2009) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2009.05.008 · Cited by 254
Self-citationMycophenolate Mofetil Therapy for Inflammatory Eye Disease
Thorne, J. E., Jabs, D. A., Qazi, F. A., Nguyen, Q. D., Kempen, J. H., & Dunn, J. P. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2005.02.020 · Cited by 219
Self-citation
Cited by
Understanding uveitis: The impact of research on visual outcomes
de Smet, M. D., Taylor, S. R. J., Bodaghi, B., Miserocchi, E., Murray, P. I., Pleyer, U., Zierhut, M., Barisani-Asenbauer, T., LeHoang, P., & Lightman, S. (2011) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2011.06.005 · Cited by 340
Pasadhika, S., & Rosenbaum, J. T. (2015) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2015.08.009 · Cited by 267
Self-citationRathinam, S. R., Babu, M., Thundikandy, R., Kanakath, A., Nardone, N., Esterberg, E., Lee, S. M., Enanoria, W. T. A., Porco, T. C., Browne, E. N., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.04.023 · Cited by 110
Corticosteroid-sparing therapy: practice patterns among uveitis specialists
Esterberg, E., & Acharya, N. R. (2012) · Journal of Ophthalmic Inflammation and Infection · doi:10.1007/s12348-011-0047-5 · Cited by 58
Wilson, L., Lewis, K. E., Evans, L. S., Dillon, S. R., & Pepple, K. L. (2023) · Translational Vision Science & Technology · doi:10.1167/tvst.12.3.27 · Cited by 5
Metadata
- Authors
- Daniel, E., Thorne, J. E., Newcomb, C. W., Pujari, S. S., Kaçmaz, R. O., Levy-Clarke, G. A., Nussenblatt, R. B., Rosenbaum, J. T., Suhler, E. B., Foster, C. S., Jabs, D. A., & Kempen, J. H.
- Venue
- American Journal of Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2010-03
- Volume
- 149
- Issue
- 3
- Pages
- 423-432.e2
- ISSN
- 0002-9394 (ISSN-L)
- OpenAlex
- W2055913604
- Cited by
- 257
- References
- 25
- FWCI
- 11.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mycophenolate Mofetil for Ocular Inflammation. https://app.cochat.ai/papers/10.1016/j.ajo.2009.09.026
- The paper
- Daniel, E., Thorne, J. E., Newcomb, C. W., Pujari, S. S., Kaçmaz, R. O., Levy-Clarke, G. A., Nussenblatt, R. B., Rosenbaum, J. T., Suhler, E. B., Foster, C. S., Jabs, D. A., & Kempen, J. H. (2010). Mycophenolate Mofetil for Ocular Inflammation. American Journal of Ophthalmology. https://doi.org/10.1016/j.ajo.2009.09.026
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.